Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum

NCT00046189 | Completed

• 2 other identifiers: 02031302-C-0313
• Study Type: observational
• Target: 301
• Locations: 1 country
• Sites: 1

Brief Summary

This study will determine if family members of patients with xeroderma pigmentosum (XP) have various abnormalities, including: skin abnormalities; nervous system abnormalities, such as hearing problems; skin, eye, or internal cancers, or other changes. XP is a rare inherited disease that involves an inability to repair damage to cell DNA (genetic material). It can affect several organ systems, including the skin, eye, nervous system, and bones. Patients have a more than thousand-fold increase in frequency in all major skin cancers. Parents of patients with XP are carriers of the abnormal XP gene. Other family members may also be carriers of the abnormal XP gene. Carriers do not develop the disease themselves; symptoms develop only in children who have inherited the faulty gene from both parents. This study will try to clarify the genetic basis for XP and to understand the increased frequency of cancer in the disease. XP patients who have been evaluated at the NIH Clinical Center and their relatives are eligible for this study. Newly diagnosed XP patients are also eligible. Spouses of relatives will also be included as control subjects. Patients and their family members will undergo some or all of the following procedures:

• Parental permission to review the child s relevant medical records and pathology material from treatments or surgery for cancer or other related illnesses
• Medical history and physical examination, with particular attention to the skin and possible eye, hearing or neurological examinations
• Photographs to document skin and other physical findings
• Nuclear medicine scans to evaluate the brain and nervous system
• X-rays of the skull or other parts of the body
• Nervous system testing with an electroencephalogram (EEG), electroretinogram (ERG), electromyogram (EMG) or nerve conduction velocity measurement
• Collection of blood and skin samples for gene studies
• Establishment of cell lines from collected blood or tissues to study DNA repair, skin cancer, cancers related to XP, immune defects, and related studies.
• Biopsy (surgical removal of a small piece of tissue) of suspicious skin lesions for examination under a microscope
• Collection of a cheek cell sample, obtained by twirling a soft brush against the inside of the cheek
• Collection of a hair sample for microscopic examination and composition analysis
• Surgery to treat skin cancers or other lesions

Conditions

Xeroderma Pigmentosum; Basal Cell Carcinoma; Squamous Cell Carcinoma; Melanoma; Skin Cancer

Keywords

Sun Exposure; Xeroderma Pigmentosum; Skin Cancer; Family History; HETEROZYGOTE; Natural History; XP

Outcome Measures

Primary Outcomes (1)

• Determine increased risk of developing cancer

  risk of any type of cancer, skin cancer and cancers of the nervous system are compared in the relatives who are heterozygotes for the XP mutations and relatives who do not carry the XP mutations by calculating the odds ratios

  Annual

Study Arms (2)

1

Patients with XP

2

Family members from XP families with known DNA repair gene mutations

Eligibility Criteria

• Age: 1 Month - 99 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with XP families where the proband has previously been evaluated at the Clinical Center or is newly diagnosed

You may qualify if:

• Members of the XP families where the proband has previously been evaluated at the Clinical Center or is newly diagnosed under other approved protocols (primarily 99-C-0099) are eligible to participate in this study. Families with XP patients of any age (excluding neonates), gender or race are eligible for this study.
• Ability of patient or Legally Authorized Representative (LAR) to sign a written informed consent document

You may not qualify if:

• Inability or unwillingness to provide family history information or tissue (skin, blood, buccal cells or hair) for laboratory studies.

Sponsors & Collaborators

• National Cancer Institute (NCI): lead

Study Sites (1)

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

Location

Related Links

• NIH Clinical Center Detailed Web Page

MeSH Terms

Conditions

Xeroderma Pigmentosum; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Melanoma; Skin Neoplasms

Condition Hierarchy (Ancestors)

Precancerous Conditions; Neoplasms; Skin Abnormalities; Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin Diseases, Genetic; Genetic Diseases, Inborn; Photosensitivity Disorders; Skin Diseases; Skin and Connective Tissue Diseases; Pigmentation Disorders; DNA Repair-Deficiency Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms, Basal Cell; Neoplasms, Squamous Cell; Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Nevi and Melanomas; Neoplasms by Site

Study Officials

• Kenneth H Kraemer, M.D.

  National Cancer Institute (NCI)

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: NIH
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 21, 2002
• First Posted: September 23, 2002
• Study Start: April 7, 2003
• Primary Completion: January 5, 2024
• Study Completion: January 5, 2024
• Last Updated: January 8, 2024

Record last verified: 2024-01

Locations

US (1)